RBC Capital raised the firm’s price target on Haleon (HLN) to 350 GBp from 330 GBp and keeps a Sector Perform rating on the shares.

In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with ...

The media giant would separate from the Paris-based conglomerate and is expected to float in London on 16 December, according ...

Pfizer (NYSE: PFE) is in that group, in my opinion. The big drugmaker's forward dividend yield currently stands at just under ...

Q3 2024 Sales Conference Call October 31, 2024 5:00 AM ETCompany ParticipantsRakesh Patel - Director of Investor ...

Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

Pfizer, which is under pressure from activist investor Starboard, on Tuesday (Oct 29) topped third-quarter estimates as sales of its Covid-19 treatment Paxlovid blew past Wall Street expectations.

A moment of truth beckons for carmakers Stellantis NV and Aston Martin Lagonda Global Holdings Plc, both of which slashed their forecasts in the run-up to this week’s earnings reports.

Following on from quarterly reports by three of the UK's big banks — Lloyds ( LLOY.L ), Barclays ( BARC.L) and NatWest ( ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month ... which include GSK’s Haleon spinout and Proctor & Gamble as well as the larger market.